Neuroprotection in glaucoma

Indian Journal of Ophthalmology

Volumn 59, Issue SUPPL. 1, 2011, Pages

  Vasudevan, Sushil K ^a,b   Gupta, Viney ^b   Crowston, Jonathan G ^c  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITI TEKNOLOGI MARA   (Malaysia)

^c ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Glaucoma; neuroprotection; pathophysiology; pharmacological approach

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; NEUROPROTECTIVE AGENT; PROSTAGLANDIN;

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; EVIDENCE BASED MEDICINE; GLAUCOMA; HUMAN; METHODOLOGY; PATHOPHYSIOLOGY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENERGIC ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; CARBONIC ANHYDRASE INHIBITORS; CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; GLAUCOMA; HUMANS; NEUROPROTECTIVE AGENTS; PROSTAGLANDINS;

EID: 78650810887     PISSN: 03014738     EISSN: 19983689     Source Type: Journal    
DOI: 10.4103/0301-4738.73700     Document Type: Conference Paper

References (161)

1. The Advanced Glaucoma Intervention Study (AGIS): 1. Study design and methods and baseline characteristics of study patients. Control Clin Trials 1994;15:299-325.
2. The advanced glaucoma intervention study, 6: Effect of cataract on visual field and visual acuity. The AGIS Investigators. Arch Ophthalmol 2000;118:1639-52.
3. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group. Am J Ophthalmol 1998;126:487-97.
4. Sommer A. Collaborative normal-tension glaucoma study. Am J Ophthalmol 1999;128:776-7.
5. Lichter PR, Musch DC, Gillespie BW, Guire KE, Janz NK, Wren PA, et al. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53.
6. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79.
7. Weinreb RN, Levin LA. Is neuroprotection a viable therapy for glaucoma? Arch Ophthalmol 1999;117:1540-4.
8. Weinreb RN. Glaucoma neuroprotection. Philadelphia, Pa.: Lippincott Williams and Wilkins; 2006.
9. Kaushik S, Pandav SS, Ram J. Neuroprotection in glaucoma. J Postgrad Med 2003;49:90-5.
10. Levin LA. Relevance of the site of injury of glaucoma to neuroprotective strategies. Surv Ophthalmol 2001;45:S243-9.
11. Gupta N, Yucel YH. Should we treat the brain in glaucoma? Can J Ophthalmol 2007;42:409-13.
12. Arundine M, Tymianski M. Molecular mechanisms of calciumdependent neurodegeneration in excitotoxicity. Cell Calcium 2003;34:325-37.
13. Sucher NJ, Lipton SA, Dreyer EB. Molecular basis of glutamate toxicity in retinal ganglion cells. Vision Res 1997;37:3483-93.
14. Vorwerk CK, Lipton SA, Zurakowski D, Hyman BT, Sabel BA, Dreyer EB. Chronic low-dose glutamate is toxic to retinal ganglion cells. Toxicity blocked by memantine. Invest Ophthalmol Vis Sci 1996;37:1618-24.
15. McKinnon SJ. Glaucoma, apoptosis, and neuroprotection. Curr Opin Ophthalmol 1997;8:28-37.
16. Quigley HA, McKinnon SJ, Zack DJ, Pease ME, Kerrigan-Baumrind LA, Kerrigan DF, et al. Retrograde axonal transport of BDNF in retinal ganglion cells is blocked by acute IOP elevation in rats. Invest Ophthalmol Vis Sci 2000;41:3460-6.
17. Pease ME, McKinnon SJ, Quigley HA, Kerrigan-Baumrind LA, Zack DJ. Obstructed axonal transport of BDNF and its receptor TrkB in experimental glaucoma. Invest Ophthalmol Vis Sci 2000;41:764-74.
18. Raff MC. Social controls on cell survival and cell death. Nature 1992;356:397-400.
19. Raff MC, Barres BA, Burne JF, Coles HS, Ishizaki Y, Jacobson MD. Programmed cell death and the control of cell survival: Lessons from the nervous system. Science 1993;262:695-700.
20. Huang EJ, Reichardt LF. Trk receptors: Roles in neuronal signal transduction. Annu Rev Biochem 2003;72:609-42.
21. Chau RM, Ren F, Huang WQ. Programmed cell death of neonatal rat retinal ganglion cells due to turn-off expression of a novel 30-kD trophic factor and/or the lack of this factor supplied from the superior colliculus. Ann N Y Acad Sci 1992;663:466-70.
22. Nurcombe V, Bennett MR. Embryonic chick retinal ganglion cells identified "in vitro". Their survival is dependent on a factor from the optic tectum. Exp Brain Res 1981;44:249-58.
23. Rabacchi SA, Ensini M, Bonfanti L, Gravina A, Maffei L. Nerve growth factor reduces apoptosis of axotomized retinal ganglion cells in the neonatal rat. Neuroscience 1994;63:969-73.
24. Thoenen H, Barde YA, Davies AM, Johnson JE. Neurotrophic factors and neuronal death. Ciba Found Symp 1987;126:82-95.
25. Ginty DD, Segal RA. Retrograde neurotrophin signaling: Trk-ing along the axon. Curr Opin Neurobiol 2002;12:268-74.
26. Quigley HA. Neuronal death in glaucoma. Prog Retin Eye Res 1999;18:39-57.
27. Carpenter P, Sefton AJ, Dreher B, Lim WL. Role of target tissue in regulating the development of retinal ganglion cells in the albino rat: Effects of kainate lesions in the superior colliculus. J Comp Neurol 1986;251:240-59.
28. Pearson HE, Stoffler DJ. Retinal ganglion cell degeneration following loss of postsynaptic target neurons in the dorsal lateral geniculate nucleus of the adult cat. Exp Neurol 1992;116:163-71.
29. Pearson HE, Thompson TP. Atrophy and degeneration of ganglion cells in central retina following loss of postsynaptic target neurons in the dorsal lateral geniculate nucleus of the adult cat. Exp Neurol 1993;119:113-9.
30. Lipton SA, Nicotera P. Calcium, free radicals and excitotoxins in neuronal apoptosis. Cell Calcium 1998;23:165-71.
31. Leung CK, Lindsey JD, Crowston JG, Lijia C, Chiang S, Weinreb RN. Longitudinal profile of retinal ganglion cell damage after optic nerve crush with blue-light confocal scanning laser ophthalmoscopy. Invest Ophthalmol Vis Sci 2008;49:4898-902.
32. Adams JM, Cory S. The Bcl-2 protein family: Arbiters of cell survival. Science 1998;281:1322-6.
33. Merry DE, Korsmeyer SJ. Bcl-2 gene family in the nervous system. Annu Rev Neurosci 1997;20:245-67.
34. Tatton WG, Chalmers-Redman RM, Sud A, Podos SM, Mittag TW. Maintaining mitochondrial membrane impermeability. an opportunity for new therapy in glaucoma? Surv Ophthalmol 2001;45:S277-83.
35. Malik JM, Shevtsova Z, Bahr M, Kugler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol Ther 2005;11:373-81.
36. Libby RT, Li Y, Savinova OV, Barter J, Smith RS, Nickells RW, et al. Susceptibility to neurodegeneration in a glaucoma is modified by Bax gene dosage. PLoS Genet 2005;1:17-26.
37. Hanninen VA, Pantcheva MB, Freeman EE, Poulin NR, Grosskreutz CL. Activation of caspase 9 in a rat model of experimental glaucoma. Curr Eye Res 2002;25:389-95.
38. McKinnon SJ, Lehman DM, Kerrigan-Baumrind LA, Merges CA, Pease ME, Kerrigan DF, et al. Caspase activation and amyloid precursor protein cleavage in rat ocular hypertension. Invest Ophthalmol Vis Sci 2002;43:1077-87.
39. McKinnon SJ, Lehman DM, Tahzib NG, Ransom NL, Reitsamer HA, Liston P, et al. Baculoviral IAP repeat-containing-4 protects optic nerve axons in a rat glaucoma model. Mol Ther 2002;5:780-7.
40. Levin LA WR, Di Polo A. A Pocket Guide of Neuroprotection in Glaucoma. New York: Ethis Communications; 2007.
41. Das A, Garner DP, Del Re AM, Woodward JJ, Kumar DM, Agarwal N, et al. Calpeptin provides functional neuroprotection to rat retinal ganglion cells following Ca2+ influx. Brain Res 2006;1084:146-57.
42. Tsai DC, Hsu WM, Chou CK, Chen SJ, Peng CH, Chi CW, et al. Significant variation of the elevated nitric oxide levels in aqueous humor from patients with different types of glaucoma. Ophthalmologica 2002;216:346-50.
43. Neufeld AH, Hernandez MR, Gonzalez M. Nitric oxide synthase in the human glaucomatous optic nerve head. Arch Ophthalmol 1997;115:497-503. (Pubitemid 27172706)
44. Motallebipour M, Rada-Iglesias A, Jansson M, Wadelius C. The promoter of inducible nitric oxide synthase implicated in glaucoma based on genetic analysis and nuclear factor binding. Mol Vis 2005;11:950-7.
45. Yuan L, Neufeld AH. Activated microglia in the human glaucomatous optic nerve head. J Neurosci Res 2001;64:523-32.
46. Liu B, Neufeld AH. Expression of nitric oxide synthase-2 (NOS-2) in reactive astrocytes of the human glaucomatous optic nerve head. Glia 2000;30:178-86.
47. Aslan M, Yucel I, Akar Y, Yucel G, Ciftcioglu MA, Sanlioglu S. Nitrotyrosine formation and apoptosis in rat models of ocular injury. Free Radic Res 2006;40:147-53.
48. Blute TA, Lee MR, Eldred WD. Direct imaging of NMDAstimulated nitric oxide production in the retina. Vis Neurosci 2000;17:557-66.
49. Cheon EW, Park CH, Kang SS, Cho GJ, Yoo JM, Song JK, et al. Nitric oxide synthase expression in the transient ischemic rat retina: Neuroprotection of betaxolol. Neurosci Lett 2002;330:265-9.
50. Cheon EW, Park CH, Kang SS, Cho GJ, Yoo JM, et al. Change in endothelial nitric oxide synthase in the rat retina following transient ischemia. Neuroreport 2003;14:329-33.
51. Boveris A, Chance B. The mitochondrial generation of hydrogen peroxide. General properties and effect of hyperbaric oxygen. Biochem J 1973;134:707-16.
52. Yildirim O, Ate NA, Ercan B, Mulu N, Unlü A, Tamer L, et al. Role of oxidative stress enzymes in open-angle glaucoma. Eye 2005;19:580-3.
53. Hara MR, Snyder SH. Cell signaling and neuronal death. Annu Rev Pharmacol Toxicol 2007;47:117-41.
54. Wang HG, Pathan N, Ethell IM, Krajewski S, Yamaguchi Y, Shibasaki F, et al. Ca2+-induced apoptosis through calcineurin dephosphorylation of Bad. Science 1999;284:339-43.
55. Huang W, Fileta JB, Dobberfuhl A, Filippopolous T, Guo Y, Kwon G, et al. Calcineurin cleavage is triggered by elevated intraocular pressure, and calcineurin inhibition blocks retinal ganglion cell death in experimental glaucoma. Proc Natl Acad Sci U S A 2005;102:12242-7.
56. Guo L, Moss SE, Alexander RA, Ali RR, Fitzke FW, Cordeiro MF. Retinal ganglion cell apoptosis in glaucoma is related to intraocular pressure and IOP-induced effects on extracellular matrix. Invest Ophthalmol Vis Sci 2005;46:175-82.
57. Zhang X, Cheng M, Chintala SK. Kainic acid-mediated upregulation of matrix metalloproteinase-9 promotes retinal degeneration. Invest Ophthalmol Vis Sci 2004;45:2374-83.
58. Tezel G, Yang J, Wax MB. Heat shock proteins, immunity and glaucoma. Brain Res Bull 2004;62:473-80.
59. Moalem G, Gdalyahu A, Shani Y, Otten U, Lazarovici P, Cohen IR, et al. Production of neurotrophins by activated T cells: Implications for neuroprotective autoimmunity. J Autoimmun 2000;15:331-45.
60. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999;5:49-55.
61. Schori H, Kipnis J, Yoles E, WoldeMussie E, Ruiz G, Wheeler LA, et al. Vaccination for protection of retinal ganglion cells against death from glutamate cytotoxicity and ocular hypertension: Implications for glaucoma. Proc Natl Acad Sci U S A 2001;98:3398-403.
62. Kipnis J, Yoles E, Porat Z, Cohen A, Mor F, Sela M, et al. T cell immunity to copolymer 1 confers neuroprotection on the damaged optic nerve: Possible therapy for optic neuropathies. Proc Natl Acad Sci U S A 2000;97:7446-51.
63. Gass A, Flammer J, Linder L, Romerio SC, Gasser P, Haefeli WE. Inverse correlation between endothelin-1-induced peripheral microvascular vasoconstriction and blood pressure in glaucoma patients. Graefes Arch Clin Exp Ophthalmol 1997;235:634-8.
64. Tezel G, Kass MA, Kolker AE, Becker B, Wax MB. Plasma and aqueous humor endothelin levels in primary open-angle glaucoma. J Glaucoma 1997;6:83-9.
65. Wirostko B, Ehrlich R, Harris A. The vascular theory in glaucoma. Glaucoma Today 2009; p. 25-7.
66. Tezel G. TNF-alpha signaling in glaucomatous neurodegeneration. Prog Brain Res 2008;173:409-21.
67. Barkana Y, Belkin M. Neuroprotection in ophthalmology: A review. Brain Res Bull 2004;62:447-53.
68. Nouri-Mahdavi K, Hoffman D, Coleman AL, Liu G, Li G, Gaasterland D, et al. Predictive factors for glaucomatous visual field progression in the Advanced Glaucoma Intervention Study. Ophthalmology 2004;111:1627-35.
69. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000;9:134-42.
70. Chaudhary P, Ahmed F, Sharma SC. MK801-a neuroprotectant in rat hypertensive eyes. Brain Res 1998;792:154-8.
71. Russo R, Cavaliere F, Berliocchi L, Nucci C, Gliozzi M, Mazzei C, et al. Modulation of pro-survival and death-associated pathways under retinal ischemia/reperfusion: Effects of NMDA receptor blockade. J Neurochem 2008;107:1347-57.
72. Seif el Nasr M, Peruche B, Rossberg C, Mennel HD, Krieglstein J. Neuroprotective effect of memantine demonstrated in vivo and in vitro. Eur J Pharmacol 1990;185:19-24.
73. Lipton SA. Prospects for clinically tolerated NMDA antagonists: Open-channel blockers and alternative redox states of nitric oxide. Trends Neurosci 1993;16:527-32.
74. Kim TW, Kim DM, Park KH, Kim H. Neuroprotective effect of memantine in a rabbit model of optic nerve ischemia. Korean J Ophthalmol 2002;16:1-7.
75. Osborne NN. Recent clinical findings with memantine should not mean that the idea of neuroprotection in glaucoma is abandoned. Acta Ophthalmol 2009;87:450-4.
76. Chidlow G, Wood JP, Casson RJ. Pharmacological neuroprotection for glaucoma. Drugs 2007;67:725-59.
77. Peinado-Ramon P, Salvador M, Villegas-Perez MP, Vidal-Sanz M. Effects of axotomy and intraocular administration of NT-4, NT-3, and brain-derived neurotrophic factor on the survival of adult rat retinal ganglion cells. A quantitative in vivo study. Invest Ophthalmol Vis Sci 1996;37:489-500.
78. Mansour-Robaey S, Clarke DB, Wang YC, Bray GM, Aguayo AJ. Effects of ocular injury and administration of brain-derived neurotrophic factor on survival and regrowth of axotomized retinal ganglion cells. Proc Natl Acad Sci U S A 1994;91:1632-6.
79. Ji JZ, Elyaman W, Yip HK, Lee VW, Yick LW, Hugon J, et al. CNTF promotes survival of retinal ganglion cells after induction of ocular hypertension in rats: The possible involvement of STAT3 pathway. Eur J Neurosci 2004;19:265-72.
80. Fu QL, Li X, Yip HK, Shao Z, Wu W, Mi S, et al. Combined effect of brain-derived neurotrophic factor and LINGO-1 fusion protein on long-term survival of retinal ganglion cells in chronic glaucoma. Neuroscience 2009;162:375-82.
81. Nickells RW. Apoptosis of retinal ganglion cells in glaucoma: An update of the molecular pathways involved in cell death. Surv Ophthalmol 1999;43:S151-61.
82. Zhou X, Li F, Kong L, Tomita H, Li C, Cao W. Involvement of inflammation, degradation, and apoptosis in a mouse model of glaucoma. J Biol Chem 2005;280:31240-8.
83. Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS. Calcium, ATP, and ROS: A mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004;287:C817-33.
84. Osborne NN, Wood JP, Chidlow G, Bae JH, Melena J, Nash MS. Ganglion cell death in glaucoma: What do we really know? Br J Ophthalmol 1999;83:980-6.
85. Osborne NN. Pathogenesis of ganglion cell death in glaucoma and neuroprotection: Focus on ganglion cell axonal mitochondria. Prog Brain Res 2008;173:339-52.
86. Tatton W, Chen D, Chalmers-Redman R, Wheeler L, Nixon R, Tatton N. Hypothesis for a common basis for neuroprotection in glaucoma and Alzheimer's disease: Anti-apoptosis by alpha-2-adrenergic receptor activation. Surv Ophthalmol 2003;48:S25-37.
87. Chaudhary P, Ahmed F, Quebada P, Sharma SC. Caspase inhibitors block the retinal ganglion cell death following optic nerve transection. Brain Res Mol Brain Res 1999;67:36-45.
88. Kermer P, Klocker N, Labes M, Bahr M. Inhibition of CPP32-like proteases rescues axotomized retinal ganglion cells from secondary cell death in vivo. J Neurosci 1998;18:4656-62.
89. Kermer P, Klocker N, Labes M, Thomsen S, Srinivasan A, Bahr M. Activation of caspase-3 in axotomized rat retinal ganglion cells in vivo. FEBS Lett 1999;453:361-4.
90. Vidal-Sanz M, Lafuente M, Sobrado-Calvo P, Selles-Navarro I, Rodriguez E, Mayor-Torroglosa S, et al. Death and neuroprotection of retinal ganglion cells after different types of injury. Neurotox Res 2000;2:215-27.
91. Kurimoto T, Miyoshi T, Suzuki A, Yakura T, Watanabe M, Mimura O, et al. Apoptotic death of beta cells after optic nerve transection in adult cats. J Neurosci 2003;23:4023-8.
92. Govindarajan B, Laird J, Sherman R, Salomon RG, Bhattacharya SK. Neuroprotection in glaucoma using calpain-1 inhibitors: Regional differences in calpain-1 activity in the trabecular meshwork, optic nerve and implications for therapeutics. CNS Neurol Disord Drug Targets 2008;7:295-304.
93. Neufeld AH, Das S, Vora S, Gachie E, Kawai S, Manning PT, et al. A prodrug of a selective inhibitor of inducible nitric oxide synthase is neuroprotective in the rat model of glaucoma. J Glaucoma 2002;11:221-5.
94. Kashiwagi K, Iizuka Y, Tsukahara S. Neuroprotective effects of nipradilol on purified cultured retinal ganglion cells. J Glaucoma 2002;11:231-8.
95. Nakazawa T, Tomita H, Yamaguchi K, Sato Y, Shimura M, Kuwahara S, et al. Neuroprotective effect of nipradilol on axotomized rat retinal ganglion cells. Curr Eye Res 2002;24:114-22.
96. Pang IH, Johnson EC, Jia L, Cepurna WO, Shepard AR, Hellberg MR, et al. Evaluation of inducible nitric oxide synthase in glaucomatous optic neuropathy and pressure-induced optic nerve damage. Invest Ophthalmol Vis Sci 2005;46:1313-21.
97. Aydemir O, Naziroglu M, Celebi S, Yilmaz T, Kukner AS. Antioxidant effects of alpha-, gamma-and succinate-tocopherols in guinea pig retina during ischemia-reperfusion injury. Pathophysiology 2004;11:167-71.
98. Dilsiz N, Sahaboglu A, Yildiz MZ, Reichenbach A. Protective effects of various antioxidants during ischemia-reperfusion in the rat retina. Graefes Arch Clin Exp Ophthalmol 2006;244:627-33.
99. Janssens D, Michiels C, Delaive E, Eliaers F, Drieu K, Remacle J. Protection of hypoxia-induced ATP decrease in endothelial cells by ginkgo biloba extract and bilobalide. Biochem Pharmacol 1995;50:991-9.
100. Netland PA, Chaturvedi N, Dreyer EB. Calcium channel blockers in the management of low-tension and open-angle glaucoma. Am J Ophthalmol 1993;115:608-13. (Pubitemid 23137645)
101. Osborne NN, Chidlow G, Wood JP, Schmidt KG, Casson R, Melena J. Expectations in the treatment of retinal diseases: Neuroprotection. Curr Eye Res 2001;22:321-32.
102. Yang H, Hirooka K, Fukuda K, Shiraga F. Neuroprotective Effects of Angiotensin II Type 1 Receptor Blocker in a Rat Model of Chronic Glaucoma. Invest Ophthalmol Vis Sci 2009;50:5800-4.
103. Lam TT, Fu J, Hrynewycz M, Tso MO. The effect of aurintricarboxylic acid, an endonuclease inhibitor, on ischemia/reperfusion damage in rat retina. J Ocul Pharmacol Ther 1995;11:253-9.
104. Butovsky O, Koronyo-Hamaoui M, Kunis G, Ophir E, Landa G, Cohen H, et al. Glatiramer acetate fights against Alzheimer's disease by inducing dendritic-like microglia expressing insulin-like growth factor 1. Proc Natl Acad Sci U S A 2006;103:11784-9.
105. Yin Y, Cui Q, Li Y, Irwin N, Fischer D, Harvey AR, et al. Macrophage-derived factors stimulate optic nerve regeneration. J Neurosci 2003;23:2284-93.
106. Simard AR, Soulet D, Gowing G, Julien JP, Rivest S. Bone marrowderived microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. Neuron 2006;49:489-502.
107. Butovsky O, Hauben E, Schwartz M. Morphological aspects of spinal cord autoimmune neuroprotection: Colocalization of T cells with B7-2 (CD86) and prevention of cyst formation. FASEB J 2001;15:1065-7.
108. Butovsky O, Talpalar AE, Ben-Yaakov K, Schwartz M. Activation of microglia by aggregated beta-amyloid or lipopolysaccharide impairs MHC-II expression and renders them cytotoxic whereas IFN-gamma and IL-4 render them protective. Mol Cell Neurosci 2005;29:381-93.
109. Barouch R, Schwartz M. Autoreactive T cells induce neurotrophin production by immune and neural cells in injured rat optic nerve: Implications for protective autoimmunity. FASEB J 2002;16:1304-6.
110. Shaked I, Tchoresh D, Gersner R, Meiri G, Mordechai S, Xiao X, et al. Protective autoimmunity: Interferon-gamma enables microglia to remove glutamate without evoking inflammatory mediators. J Neurochem 2005;92:997-1009.
111. Kipnis J, Cardon M, Avidan H, Lewitus GM, Mordechay S, Rolls A, et al. Dopamine, through the extracellular signal-regulated kinase pathway, downregulates CD4+CD25+ regulatory T-cell activity: Implications for neurodegeneration. J Neurosci 2004;24:6133-43.
112. Kipnis J, Mizrahi T, Hauben E, Shaked I, Shevach E, Schwartz M. Neuroprotective autoimmunity: Naturally occurring CD4+CD25+ regulatory T cells suppress the ability to withstand injury to the central nervous system. Proc Natl Acad Sci U S A 2002;99:15620-5.
113. Ishii Y, Kwong JM, Caprioli J. Retinal ganglion cell protection with geranylgeranylacetone, a heat shock protein inducer, in a rat glaucoma model. Invest Ophthalmol Vis Sci 2003;44:1982-92. (Pubitemid 36520289)
114. Bull ND, Johnson TV, Martin KR. Stem cells for neuroprotection in glaucoma. Prog Brain Res 2008;173:511-9.
115. Frank T, Schlachetzki JC, Göricke B, Meuer K, Rohde G, Dietz GP, et al. Both systemic and local application of granulocyte-colony stimulating factor (G-CSF) is neuroprotective after retinal ganglion cell axotomy. BMC Neurosci 2009;10:49.
116. Bull ND, Irvine KA, Franklin RJ, Martin KR. Transplanted oligodendrocyte precursor cells reduce neurodegeneration in a model of glaucoma. Invest Ophthalmol Vis Sci 2009;50:4244-53.
117. Kong GY, Van Bergen NJ, Trounce IA, Crowston JG. Mitochondrial dysfunction and glaucoma. J Glaucoma 2009;18:93-100.
118. Schober MS, Chidlow G, Wood JP, Casson RJ. Bioenergetic-based neuroprotection and glaucoma. Clin Experiment Ophthalmol 2008;36:377-85.
119. Wheeler DS, Jensen RA, Poss WB. A randomized, blinded comparison of chloral hydrate and midazolam sedation in children undergoing echocardiography. Clin Pediatr (Phila) 2001;40:381-7.
120. Kalapesi FB, Coroneo MT, Hill MA. Human ganglion cells express the alpha-2 adrenergic receptor: Relevance to neuroprotection. Br J Ophthalmol 2005;89:758-63.
121. Gao H, Qiao X, Cantor LB, WuDunn D. Up-regulation of brainderived neurotrophic factor expression by brimonidine in rat retinal ganglion cells. Arch Ophthalmol 2002;120:797-803.
122. Donello JE, Padillo EU, Webster ML, Wheeler LA, Gil DW. Alpha(2)-Adrenoceptor agonists inhibit vitreal glutamate and aspartate accumulation and preserve retinal function after transient ischemia. J Pharmacol Exp Ther 2001;296:216-23.
123. Wheeler LA, Tatton NA, Elstner M, al e. Alpha-2 adrenergic receptor activation by brimonidine reduces neuronal apoptosis through Akt (Protein Kinase B) dependent new synthesis of BCL-2. Invest Ophthalmol Vis Sci 2001;42:S411.
124. Ballif BA, Blenis J. Molecular mechanisms mediating mammalian mitogen-activated protein kinase (MAPK) kinase (MEK)-MAPK cell survival signals. Cell Growth Differ 2001;12:397-408.
125. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 1995;270:1326-31.
126. Dong CJ, Guo Y, Agey P, Wheeler L, Hare WA. Alpha2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci 2008;49:4515-22.
127. Krupin T, Liebmann JM, Greenfield DS, Rosenberg LF, Ritch R, Yang JW. The Low-pressure Glaucoma Treatment Study (LoGTS) study design and baseline characteristics of enrolled patients. Ophthalmology 2005;112:376-85.
128. Osborne NN, Wood JP, Chidlow G. Invited review: Neuroprotective properties of certain beta-adrenoceptor antagonists used for the treatment of glaucoma. J Ocul Pharmacol Ther 2005;21:175-81.
129. Baptiste DC, Hartwick AT, Jollimore CA, Baldridge WH, Chauhan BC, Tremblay F, et al. Comparison of the neuroprotective effects of adrenoceptor drugs in retinal cell culture and intact retina. Invest Ophthalmol Vis Sci 2002;43:2666-76.
130. Gross RL, Hensley SH, Gao F, Wu SM. Retinal ganglion cell dysfunction induced by hypoxia and glutamate: Potential neuroprotective effects of beta-blockers. Surv Ophthalmol 1999;43:S162-70.
131. Hirooka K, Kelly ME, Baldridge WH, Barnes S. Suppressive actions of betaxolol on ionic currents in retinal ganglion cells may explain its neuroprotective effects. Exp Eye Res 2000;70:611-21.
132. Melena J, Stanton D, Osborne NN. Comparative effects of antiglaucoma drugs on voltage-dependent calcium channels. Graefes Arch Clin Exp Ophthalmol 2001;239:522-30.
133. Zhang J, Wu SM, Gross RL. Effects of beta-adrenergic blockers on glutamate-induced calcium signals in adult mouse retinal ganglion cells. Brain Res 2003;959:111-9.
134. Chidlow G, Melena J, Osborne NN. Betaxolol, a beta(1)-adrenoceptor antagonist, reduces Na(+) influx into cortical synaptosomes by direct interaction with Na(+) channels: Comparison with other beta-adrenoceptor antagonists. Br J Pharmacol 2000;130:759-66.
135. Melena J, Wood JP, Osborne NN. Betaxolol, a beta1-adrenoceptor antagonist, has an affinity for L-type Ca2+ channels. Eur J Pharmacol 1999;378:317-22.
136. Tan AY, LeVatte TL, Archibald ML, Tremblay F, Kelly ME, Chauhan BC. Timolol concentrations in rat ocular tissues and plasma after topical and intraperitoneal dosing. J Glaucoma 2002;11:134-42.
137. Osborne NN, DeSantis L, Bae JH, Ugarte M, Wood JP, Nash MS, et al. Topically applied betaxolol attenuates NMDA-induced toxicity to ganglion cells and the effects of ischaemia to the retina. Exp Eye Res 1999;69:331-42.
138. DeSantis L, Dahlin D, Barnes G. A role for the calcium channel blocking-like action of betaxolol for providing therapeutic benefit to glaucoma patients. In: Drance S, editor. Update to glaucoma, ocular blood flow, and drug treatment. Amsterdam;New York: Kugler Publications; 1995. p. 137-43.
139. Goto W, Ota T, Morikawa N, Otori Y, Hara H, Kawazu K, et al. Protective effects of timolol against the neuronal damage induced by glutamate and ischemia in the rat retina. Brain Res 2002;958:10-9.
140. Messmer C, Flammer J, Stumpfig D. Influence of betaxolol and timolol on the visual fields of patients with glaucoma. Am J Ophthalmol 1991;112:678-81.
141. Collignon-Brach J. Long-term effect of ophthalmic betaadrenoceptor antagonists on intraocular pressure and retinal sensitivity in primary open-angle glaucoma. Curr Eye Res 1992;11:1-3.
142. Collignon-Brach J. Longterm effect of topical beta-blockers on intraocular pressure and visual field sensitivity in ocular hypertension and chronic open-angle glaucoma. Surv Ophthalmol 1994;38:S149-55.
143. Kaiser HJ, Flammer J, Stumpfig D, Hendrickson P. Longterm visual field follow-up of glaucoma patients treated with beta-blockers. Surv Ophthalmol 1994;38:S156-9.
144. Drance SM. A comparison of the effects of betaxolol, timolol, and pilocarpine on visual function in patients with open-angle glaucoma. J Glaucoma 1998;7:247-52.
145. Vainio-Jylha E, Vuori ML. The favorable effect of topical betaxolol and timolol on glaucomatous visual fields: A 2-year follow-up study. Graefes Arch Clin Exp Ophthalmol 1999;237:100-4.
146. Araie M, Azuma I, Kitazawa Y. Influence of topical betaxolol and timolol on visual field in Japanese open-angle glaucoma patients. Jpn J Ophthalmol 2003;47:199-207.
147. Rainer G, Dorner GT, Garhofer G, Vass C, Pfleger T, Schmetterer L. Changing antiglaucoma therapy from timolol to betaxolol: Effect on ocular blood flow. Ophthalmologica 2003;217:288-93.
148. Miki H, Miki K. The effects on the intraocular pressure and visual field resulting from a switch in the treatment from timolol to betaxolol. J Ocul Pharmacol Ther 2004;20:509-17.
149. Kudo H, Nakazawa T, Shimura M, Takahashi H, Fuse N, Kashiwagi K, et al. Neuroprotective effect of latanoprost on rat retinal ganglion cells. Graefes Arch Clin Exp Ophthalmol 2006;244:1003-9.
150. Drago F, Valzelli S, Emmi I, Marino A, Scalia CC, Marino V. Latanoprost exerts neuroprotective activity in vitro and in vivo. Exp Eye Res 2001;72:479-86.
151. Melamed S. Neuroprotective properties of a synthetic docosanoid, unoprostone isopropyl: Clinical benefits in the treatment of glaucoma. Drugs Exp Clin Res 2002;28:63-73.
152. Hare WA, WoldeMussie E, Weinreb RN, Ton H, Ruiz G, Wijono M, et al. Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures. Invest Ophthalmol Vis Sci 2004;45:2640-51. (Pubitemid 38998860)
153. Fuchsjger-Mayrl G, Wally B, Rainer G, Buehl W, Aggermann T, Kolodjaschna J, et al. Effect of dorzolamide and timolol on ocular blood flow in patients with primary open angle glaucoma and ocular hypertension. Br J Ophthalmol 2005;89:1293-7.
154. Seki M, Tanaka T, Matsuda H, Togano T, Hashimoto K, Ueda J, et al. Topically administered timolol and dorzolamide reduce intraocular pressure and protect retinal ganglion cells in a rat experimental glaucoma model. Br J Ophthalmol 2005;89:504-7.
155. Sarup V, McEwan GC, Thompson C, Patil KA, Sharma SC. Dorzolamide and timolol saves retinal ganglion cells in glaucomatous adult rats. J Ocul Pharmacol Ther 2005;21:454-62.
156. Tsai JC, Song BJ, Wu L, Forbes M. Erythropoietin: A candidate neuroprotective agent in the treatment of glaucoma. J Glaucoma 2007;16:567-71.
157. Ritch R. Natural compounds: Evidence for a protective role in eye disease. Can J Ophthalmol 2007;42:425-38.
158. Castro-Sanchez AM, Moreno-Lorenzo C, Mataran-Penarrocha GA, Feriche-Fernandez-Castanys B, Granados-Gamez G, Quesada-Rubio JM. Connective Tissue Reflex Massage for Type 2 Diabetic Patients with Peripheral Arterial Disease: Randomized Controlled Trial. Evid Based Complement Alternat Med 2009.[In Press].
159. Kusari J, Zhou S, Padillo E, Clarke KG, Gil DW. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2007;48:5152-9.
160. Wilhelm B, Ludtke H, Wilhelm H. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): A 3-month, doublemasked, randomised, placebo-controlled trial. Graefes Arch Clin Exp Ophthalmol 2006;244:551-8.
161. Weinreb RN, Gupta N, Girkin C, Goldberg I. Workshop breakout group. Toronto, Ont: International Ocular Neuroprotection symposium; 2006.